Bora Pharmaceuticals is mentioned as "the largest pharmaceutical group by volume in Taiwan" in 2022 after completing the company's "landmark acquisition" of TWi Pharmaceuticals. Published in the online version of Generics Bulletin. https://generics.pharmaintelligence.informa.com/GB152440/Standalone-Sandoz-And-Biocons-Biosimilars-2022s-Biggest-Deals Thank you Pharma Intelligence andAuthor Dean...
Fierce Pharma features a discussion with CEO, Bobby Sheng in an article entitled "After Bora's biologics debut, CEO outlines quest to join ranks of top CDMOs". Published on November 10, 2022Thank you Fierce Pharma and author Fraiser Kansteiner Bora's focus on customer partnership is key to Bora's acquisition strategy. Bora's recent addition of biologics offerings with acquisition of Eden...
Bora establishes a lead position in Taiwan's CDMO sector TAIWAN - Fast-growing contract development and manufacturing organization (CDMO), Bora Pharmaceuticals, has completed the acquisition of TWi Pharmaceutical Co.Ltd, a technology-based company specializing in development and commercialization of niche generic drugs. Acquiring TWi Pharmaceuticals adds two manufacturing facilities and will...
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market Taiwan-based premier international contract development and manufacturing organization (CDMO) Bora Pharmaceuticals recently announced the establishment of Bora Biologics Co., Ltd., a CDMO platform for biologics. Besides Bora, investors into the new entity include Taishin...